𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Daiichi Sankyo US's global head of R&D Ken Takeshita talks antibody-drug conjugates and more at the company's "Pharma Day" event in Kendall Square. From a partnering event being held at MassBio's HQ, he describes Daiichi's targets under development beyond HER2 and TROP2, plus what the company is looking at outside of ADCs. Full video: https://lnkd.in/ekautr4J BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
About us
News, stories, and educational videos about the biotechnology sector. Bringing biotech to life. 📺
- Website
-
https://www.biotechtv.com
External link for BiotechTV
- Industry
- Internet News
- Company size
- 2-10 employees
- Headquarters
- Seaport, Boston
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Biotech and News
Locations
-
Primary
Seaport, Boston, US
Employees at BiotechTV
Updates
-
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: On Wednesday, Amylyx Pharmaceuticals announced it had acquired a GLP-1 antagonist for $35.1M. Co-CEOs Joshua Cohen and Justin Klee tell us about the deal. They explain why they chose this program, and what the potential timeline looks like for a phase 3 trial. Plus, an update on Amylyx's existing pipeline, including recent data in Wolfram Syndrome. Full video: https://lnkd.in/gFGP_dk8 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐁𝐫𝐢𝐠𝐡𝐭 𝐌𝐢𝐧𝐝𝐬: The Co-Founder and CEO of Philadelphia based BioPhy describes how he sees AI playing out across the biopharma landscape. Dave Latshaw II, PhD, MBA predicts how AI might affect organizations of different sizes in biopharma and explains the various ways BioPhy is using it today to help companies. Full video: https://lnkd.in/gBt8iZTC BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐓𝐡𝐮𝐫𝐬𝐝𝐚𝐲𝐬: Stifel Institutional's Paul Matteis joins BiotechTV for Analyst Thursdays from Boston for an in-depth discussion on this week's uniQure data, and upcoming data from Lexeo. Plus, comments on Alnylam, Dyne, Neurocrine, Alector, Neumora, Alto Neuroscience, and Neurogene. Full video: https://lnkd.in/gWBzkRAu BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐁𝐞𝐡𝐢𝐧𝐝 𝐭𝐡𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞: Philadelphia-based Passage Bio is aiming to treat frontotemporal dementia by using an AAV gene therapy to boost progranulin levels in the brain. CEO Will Chou describes the scientific rationale for elevating progranulin, what the company has seen in the first three patients treated, and previews an upcoming conference in September. Full video: https://lnkd.in/g5zWV7id BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐢𝐧𝐠 𝐍𝐞𝐰𝐬: Flagship Pioneering today announced a $3.6B capital raise in its Fund VIII and side funds. Founder & CEO Noubar Afeyan discusses the details. He describes some areas that he sees the funding being deployed, his take on the current state of biotech, the IPO market, taking Flagship global, AI, and more. Full video: https://lnkd.in/gkwCTRWp BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
Get to know Allucent -- a full-service, global provider of comprehensive drug development solutions for small and mid-sized biopharmas. They're on a mission to help bring new therapies to light. Here's how they can help you. Reach out to Anita Nelsen if you'd like to learn more. #sponsored
-
𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐢𝐧𝐠 𝐍𝐞𝐰𝐬: London based Myricx Bio announced a £90M (~$114M) series A financing today, one of the largest in recent years in the UK region. A developer of ADCs today, CEO Robin Carr describes how the company’s N-myristoyltransferase (NMT) payload approach sets them apart. Full video: https://lnkd.in/gt-GapCu BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐁𝐫𝐢𝐠𝐡𝐭 𝐌𝐢𝐧𝐝𝐬: Stifel Financial Corp. analyst Alex Thompson, PhD joins BiotechTV for Analyst Thursdays and talks I&I ahead of the July 4th holiday He gives his general take on I&I and comments on argenx, Immunovant, Ascendis, Celldex, Third Harmonic, Apogee, Spyre, Viridian, Dianthus, AnaptysBio, and Pliant. Full video: https://lnkd.in/gFFF5uDX BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Mereo BioPharma's CEO Denise Scots-Knight discusses recent setrusumab data in Osteogenesis Imperfecta and the future of alvelestat. She describes what Mereo and its partner Ultragenyx have seen in setrusumab data over time, and her description of the clinical benefit to patients’ lives. Plus, the role that the company’s alvelestat program could play in lung conditions. Full video: https://lnkd.in/g7Rj336i BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent